IMMUNIC, INC.
No SEC Form 4 filings for $IMUX in the last 30 days.
See all $IMUX insider activity →Immunic, Inc. (IMUX) will host a virtual R&D day on September 9, 2026, to discuss its Phase 3 ENSURE trials for vidofludimus calcium, an oral therapy for relapsing multiple sclerosis. The company expects top-line data by the end of 2026. Key opinion leaders will share insights on MS treatment and unmet medical needs.
Immunic AG (IMUX) appointed Chitrang Davé as Chief Data and Digital Officer. Davé will lead data systems, analytics, and digital strategy, supporting NDA submission and commercialization of vidofludimus calcium (IMU-838) for multiple sclerosis. He received an option to purchase 120,000 shares.
US stocks ended lower as US-Iran talks remained unresolved amid Strait of Hormuz uncertainty. The Nasdaq fell 0.6% to 26,445, while the Dow and S&P 500 each declined 0.3%. Oil was steady near $82.50/bbl, according to IG’s Axel Rudolph. The article also cites company-specific moves including Nvidia’s $500B AI financing plan and several earnings, bids, and guidance updates.
Over the past 7 days, alphai's AI scored 3 news stories mentioning IMUX (IMMUNIC, INC.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent IMUX coverage spans financial news, technology and earnings.
The announcement may generate modest short‑term interest but no immediate catalyst for price movement.
The hire signals a focus on data infrastructure ahead of pivotal trial readouts and potential regulatory filing, which may improve operational efficiency and investor confidence.
Trial timeline confirmation reduces binary uncertainty and can support risk-on positioning for MS drug development timelines.
Near-term catalyst is year-end Phase 3 top-line data, with potential US NDA submission mid-2027 if results are positive.
Near-term catalyst is the planned Phase 3 readouts timeline and the decision to initiate a progressive MS Phase 3 study, which can shift valuation expectations for vidofludimus calcium.
alphai scores every news story that mentions IMUX with an AI model for sentiment and relevance, and aggregates insider trades from IMMUNIC, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immunic, Inc. (IMUX) will host a virtual R&D day on September 9, 2026, to discuss its Phase 3 ENSURE trials for vidofludimus calcium, an oral therapy for relapsing multiple sclerosis. The company expects top-line data by the end of 2026. Key opinion leaders will share insights on MS treatment and unmet medical needs.
1 min readImmunic AG (IMUX) appointed Chitrang Davé as Chief Data and Digital Officer. Davé will lead data systems, analytics, and digital strategy, supporting NDA submission and commercialization of vidofludimus calcium (IMU-838) for multiple sclerosis. He received an option to purchase 120,000 shares.
2 min readUS stocks ended lower as US-Iran talks remained unresolved amid Strait of Hormuz uncertainty. The Nasdaq fell 0.6% to 26,445, while the Dow and S&P 500 each declined 0.3%. Oil was steady near $82.50/bbl, according to IG’s Axel Rudolph. The article also cites company-specific moves including Nvidia’s $500B AI financing plan and several earnings, bids, and guidance updates.
7 min readImmunic Inc (NASDAQ:IMUX) said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium for relapsing multiple sclerosis remain on track for top-line data by year-end 2026. If positive, it plans a US NDA mid-2027 and a decision in 2028. Q2 operating expenses were $35.3M; net loss about $34.1M. Cash was $155.1M.
4 min readImmunic CEO Erik Lundgren discussed the company’s Q2 progress and leadership changes. He said Phase 3 ENSURE-1 and ENSURE-2 relapsing MS trials are fully enrolled and on track for year-end results, with health authorities engaged. Immunic aims to start a progressive MS Phase 3 study by year-end. Q2 cash was about $155M.
4 min readIMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Immunic Appoints Elena Ridloff to Board of Directors – Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filing
6 min readImmunic, Inc. (Nasdaq: IMUX) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its MS pipeline. Phase 3 ENSURE-1 and ENSURE-2 for vidofludimus calcium in relapsing MS remain on track for top-line data by end-2026. Progressive MS Phase 3 initiation is planned later in 2026. Total operating expenses were $35.3M for the quarter.
6 min readImmunic Inc (NASDAQ:IMUX) appointed Elena Ridloff to its board. Ridloff is CFO of Sionna Therapeutics and previously served as CFO at ACADIA Pharmaceuticals, where she helped raise $600 million. Immunic said the move supports progress toward late-stage milestones for vidofludimus calcium, including Phase 3 ENSURE top-line data expected by year-end.
2 min readThe article is a small-cap news roundup covering multiple companies. Highlights include Immunic appointing Elena Ridloff to its board, First Phosphate’s Level 2 Nasdaq ADR uplisting, Thruvision’s £3m+ Asia airport contract, Caledonia Mining keeping 2026 gold output guidance, and Provaris receiving a NAV upgrade to $0.14/share. Other items include drilling updates, project progress, and management changes.
9 min readIMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001280776 0001280776 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min read
